NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Health Information Services · USD

SOPHiA GENETICS SA (SOPH) Stock Analysis

SOPHiA GENETICS SA (SOPH) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SOPH

$7.35

+$0.42 (+6.06%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SOPH with… →

SOPH Key Statistics

As of Oct 21, 2026
Trading
Open
$6.99
Previous Close
$6.93
Day's Range
6.99–7.43
52-Week Range
3.75–8.98
Volume
591.85K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$625.69M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.26
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.16
Financials (FY)
Revenue (FY)
$77.27M+18.56%
Net Income (FY)
−$79.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
−93.86%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
85.13M
1-Year Return
+75.00%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
591.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SOPH closed at $7.35, +75.00% over 1 year.

SOPHiA GENETICS SA (SOPH) has a market capitalization of $625.69M.

In fiscal 2025, SOPH reported revenue of $77.27M.

SOPH Stock Return by Calendar Year

SOPHiA GENETICS SA (SOPH) return since Jul 2021: what $10,000 became

1 year
$10,000 $17,500
+75.00%
5 years
$10,000 $4,308
−56.92%
Since Jul 2021
$10,000 $4,385
−56.15%

If you had invested $10,000 in SOPHiA GENETICS SA (SOPH) at the close on July 23, 2021, the earliest close on record here, it would have been worth $4,385 at the close on October 21, 2026: −56.15% in total, −14.54% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+57.39%
2025+52.12%
2024−34.82%
2023+128.64%
2022−85.39%
2021 (partial year)−15.87%

As of October 21, 2026.

SOPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$77.27M−$79.00M−102.2%
2024$65.17M−$62.49M−95.9%
2023$62.37M−$78.98M−126.6%
2022$47.56M−$87.45M−183.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$77.27M$52.08M−$70.91M−$79.00M−102.2%
2024$65.17M$43.94M−$66.57M−$62.49M−95.9%
2023$62.37M$42.91M−$74.83M−$78.98M−126.6%
2022$47.56M$31.25M−$87.82M−$87.45M−183.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SOPH Valuation vs Health Information Services Median

Median of 44 stocks
MetricSOPHHealth Information Services medianvs median
P/S ratio7.262.313.1x the median
Profit margin−93.86%−7.55%86.3 pts below

Medians across 44 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

SOPHiA GENETICS SA (SOPH) is capitalised at $625.69M on the latest close. The company sits in the Healthcare sector, in the Health Information Services industry. The company reports 415 employees.

The 52-week range on file runs from $3.75 to $8.98. SOPH last closed at $7.35 on October 21, 2026. That is +$0.42 (+6.06%) against the previous close. The latest close sits 96% above that 52-week low.

Financial Health

In fiscal 2025, SOPHiA GENETICS SA reported revenue of $77.27M. Against the prior fiscal year total of $65.17M, that is a change of +18.56%. The same year closed with a net loss of $79.00M. Profit margin runs at −93.86%. That is 86.3 percentage points below the Health Information Services median of −7.55%. Trailing earnings per share are −1.16.

Across the 4 fiscal years on file, revenue moves from $47.56M in 2022 to $77.27M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 7.26. On price-to-sales that is 3.1 times the Health Information Services median of 2.31. The medians here are taken across 44 Health Information Services companies that report the metric.

Beta against the wider market is reported at 0.95. Annualized volatility over the trailing 5 years is 81.64%. The trailing one-year total return is +75.00%. Across 5 years the annualized return works out at −15.50%.

Growth & Income

The record shows no dividend for SOPH.

The strongest complete calendar year on file is 2023 at +128.64%; the weakest is 2022 at −85.39%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +57.39% year to date.

Peer Comparison

SOPHiA GENETICS SA (SOPH) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
SOPHiA GENETICS SA SOPH $625.69M —
Veeva Systems Inc. VEEV $51.90B 52.6
BrightSpring Health Services, Inc. BTSG $12.40B 55.4
Tempus AI, Inc. TEM $12.23B —

The Health Information Services industry average P/E ratio is 46.5x. SOPHiA GENETICS SA has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$51.90B

 BTSG

BrightSpring Health Services, Inc.

$12.40B

 TEM

Tempus AI, Inc.

$12.23B

 HNGE

Hinge Health, Inc.

$9.04B

 HQY

HealthEquity, Inc.

$8.10B

 DOCS

Doximity, Inc.

$5.99B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About SOPHiA GENETICS SA

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Visit website →